Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
iso-Leucettinib-21
100
CHF
CHF 100.00
In stock
AG-MR-C0048-M0011 mgCHF 100.00
AG-MR-C0048-M0055 mgCHF 330.00
AG-MR-C0048-M02525 mgCHF 980.00
| Product Details | |
|---|---|
| Synonyms | iso-LCTB-21; (R,Z)-6-(Benzo[d]thiazol-5-ylmethylene)-2-((1-methoxy-4-methylpentan-2-yl)amino)-3,5-dihydro-4H-imidazol-4-one |
| Product Type | Chemical |
| Properties | |
| Formula |
C18H22N4O2S |
| MW | 358.5 |
| CAS | 3032977-73-1 |
| Purity Chemicals | ≥99% (NMR) |
| Appearance | Pale yellow to off-white powder. |
| Solubility | Soluble in DMSO (10mM) or ethanol. |
| Reconstitution | Stock solutions can be made up to 10mM in DMSO. |
| Identity | Determined by 1H-NMR. |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Protect from light and moisture. |
| Use/Stability |
Stable for at least 2 years after receipt when stored at -20°C. Store solutions at -20°C in the dark. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Kinase inactive isomer of Leucettinib-21 (IC50 DYRK1A > 10 µM). Should be used as a negative control for Leucettinb-21 (Prod. No. AG-MR-C0047).
- Does not inhibit the phosphorylation of Tau at Thr212 and cyclin D1 at Thr286, native DYRK1A in HT-22 cells and does not trigger cell apoptotic cell death.
- Does not correct cognitive deficits in Ts65Dn model of Down syndrome and other models.
Product References
- Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B: E. Deau, et al.; J. Med. Chem. 66, 10694 (2023)
- Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer’s Disease Drug Candidate: M.F. Lindberg, et al.; J. Med. Chem. 66, 15648 (2023)
- Leucettinib-21, a DYRK1A kinase inhibitor as a clinical drug candidate for Alzheimer’s disease and Down syndrome. In Therapeutic Trials in Alzheimer's Disease: Where Are We Now?: L. Meijer, et al.; J. Alzheim. Dis. (in press) (2024)
Related Products
